sCD163 in PBC Patients - Assessment of Treatment Response
Condition(s) studied
Investigational drug(s) / intervention(s)
Liver biopsy: Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
Study summary
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment.
sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
Eligibility
Primary outcome measure(s)
- UDCA response (ALP <3 times upper normal limit, AST <2 times upper normal limit, and bilirubin ≤1 mg/dL after one year of treatment) — 1 year
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark | Aarhus C | Central Jutland | Recruiting |
More University of Aarhus trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT02931513 on ClinicalTrials.gov ↗ ← All trials in Denmark